LMAT vs ZBH: fair value comparison
LeMaitre Vascular, Inc. and Zimmer Biomet Holdings, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LMAT currently sits closer to the top of our discount ranking. ZBH carries the stronger quality grade.
| LMAT | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $103.61 | $100.91 |
| 12-month range | $79.78–$111.76 | $82.90–$105.01 |
| Sector rank | #37 of 113 Healthcare | #40 of 113 Healthcare |
| Quality grade | C+ | B |
| Momentum grade | — | B |
| Leverage | Low | Moderate |
| Margin trend | — | Stable |
| Revenue growth | — | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: LMAT fair value analysis · ZBH fair value analysis